Publication:
CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES

Simple item page
dc.contributor.authorsTanaka, Y.; Li, Z.; Inanc, N.; Xavier, R.; Tilt, N.; Cara, C.; Saadoun, C.; Takeuchi, T.
dc.date.accessioned2022-03-12T16:24:44Z
dc.date.accessioned2026-01-11T09:35:02Z
dc.date.available2022-03-12T16:24:44Z
dc.date.issued2020
dc.identifier.doi10.1136/annrheumdis-2020-eular.2069
dc.identifier.eissn1468-2060
dc.identifier.issn0003-4967
dc.identifier.urihttps://hdl.handle.net/11424/226437
dc.identifier.wosWOS:000555905000452
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofANNALS OF THE RHEUMATIC DISEASES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPLUS METHOTREXATE
dc.subjectDOUBLE-BLIND
dc.subjectSAFETY
dc.titleCERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage268
oaire.citation.startPage267
oaire.citation.titleANNALS OF THE RHEUMATIC DISEASES
oaire.citation.volume79

Files

Collections

Araştırma Çıktıları